NOTCH1 and neoplasm: In fact, to date, almost all Notch1 inhibitors have largely failed in their clinical management due to gastrointestinal toxicities, non-selective Notch inhibition, and effective therapeutic doses to curb tumor growth (Imbimbo, 2008; Wu et al., 2010).